Last reviewed · How we verify

Ropivicaine

Henry Ford Health System · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Ropivicaine is a Small molecule drug developed by Henry Ford Health System. It is currently FDA-approved. Also known as: naropin, Naropin, Trans-Abdominis Plane Block, ropivicaine, naropin.

Ropivacaine is a small molecule local anesthetic drug belonging to the amino amide group. It is marketed under the brand name Naropin by AstraZeneca and has been used in various clinical trials for conditions such as pectus excavatum, mastectomy, and breast cancer.

At a glance

Generic nameRopivicaine
Also known asnaropin, Naropin, Trans-Abdominis Plane Block, ropivicaine, naropin
SponsorHenry Ford Health System
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ropivicaine

What is Ropivicaine?

Ropivicaine is a Small molecule drug developed by Henry Ford Health System.

Who makes Ropivicaine?

Ropivicaine is developed and marketed by Henry Ford Health System (see full Henry Ford Health System pipeline at /company/henry-ford-health-system).

Is Ropivicaine also known as anything else?

Ropivicaine is also known as naropin, Naropin, Trans-Abdominis Plane Block, ropivicaine, naropin.

What development phase is Ropivicaine in?

Ropivicaine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing